Published in Nat Med on August 19, 2007
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Immunity, inflammation, and cancer. Cell (2010) 28.27
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8.63
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 5.00
Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med (2010) 4.61
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature (2009) 3.93
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature (2010) 3.70
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) (2010) 2.99
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol (2010) 2.85
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol (2014) 2.59
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood (2008) 2.54
Cross-priming in health and disease. Nat Rev Immunol (2010) 2.51
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys (2014) 2.28
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity (2014) 2.28
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Targeting HMGB1 in inflammation. Biochim Biophys Acta (2009) 2.11
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A (2009) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol (2011) 1.91
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ (2008) 1.84
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity (2013) 1.75
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet (2016) 1.74
CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol (2015) 1.73
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest (2012) 1.69
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Alarmins link neutrophils and dendritic cells. Trends Immunol (2009) 1.61
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol (2009) 1.57
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Inflammation and cancer: a double-edged sword. Cancer Cell (2007) 1.52
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med (2009) 1.51
A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One (2013) 1.50
Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ (2013) 1.49
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47
The hallmarks of aging. Cell (2013) 14.29
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) 13.29
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2002) 12.09
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol (2009) 10.52
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med (2015) 10.15
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
High versus low blood-pressure target in patients with septic shock. N Engl J Med (2014) 7.37
Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med (2015) 7.02
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Autophagy and aging. Cell (2011) 5.96
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol (2004) 5.44
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35
Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23
Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci (2004) 5.19
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Control of peripheral nerve myelination by the beta-secretase BACE1. Science (2006) 4.55
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys (2006) 4.26
The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet (2002) 4.19
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 4.18
Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst (2006) 4.17
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07